Algert Global’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Algert Global’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-30,445	Closed	-$143K	–	534
2020 Q3	$143K	Hold	30,445	–	–	0.05%	338
2020 Q2	$186K	Sell	30,445 -6,770	-18%	-$27.9K	0.06%	336
2020 Q1	$84K	Sell	37,215 -2,490	-6%	-$10.6K	0.04%	362
2019 Q4	$182K	Sell	39,705 -24,334	-38%	-$96.4K	0.05%	323
2019 Q3	$248K	Buy	64,039 +16,640	+35%	+$91.3K	0.09%	247
2019 Q2	$286K	Buy	+47,399	New	+$453K	0.11%	232
2018 Q3	–	Sell	-30,138	Closed	-$476K	–	402
2018 Q2	$476K	Buy	+30,138	New	+$526K	0.1%	250

Other funds holding FPRX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Algert Global's FPRX Position: Q4 2020 in Review

Algert Global sold out of Five Prime Therapeutics, Inc. (FPRX) in Q4 2020, closing a stake of 30,445 shares — an estimated $143K sold.

Algert Global first reported a position in FPRX in Q2 2018 and held it in 7 quarters. The position peaked at $476K in Q2 2018. 125 funds tracked by Wall St. Rank hold FPRX as of Q4 2020.

Algert Global reported no remaining Five Prime Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
Algert Global sold 30,445 Five Prime Therapeutics, Inc. shares in Q4 2020, an estimated $143K.
Algert Global first reported a position in Five Prime Therapeutics, Inc. in Q2 2018 and held it in 7 quarters.
Algert Global's Five Prime Therapeutics, Inc. position peaked at $476K in Q2 2018.
125 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2020.

Based on Algert Global's 13F filing for Q4 2020, filed 12 Feb 2021.